Navigation Links
CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
Date:7/10/2008

PALO ALTO, Calif., July 10 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has received marketing authorization from the European Medicines Agency (EMEA) for ranolazine for the treatment of patients with chronic angina in all 27 European Union (EU) member states. This approval follows a positive opinion from the EMEA Committee for Medicinal Products for Human Use (CHMP) on April 24, 2008.

Ranolazine is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. Ranolazine is approved for use in 375 mg, 500 mg and 750 mg doses, administered twice daily.

The approved European labeling reflects data from the MERLIN TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. The labeling also notes that the ability of ranolazine to reduce cellular calcium overload is expected to improve myocardial relaxation and decrease left ventricular diastolic stiffness.

"We expect ranolazine could be available to patients and physicians across Europe beginning in the first part of 2009, as we continue to see very strong interest from potential commercial partners," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "Revenues from European sales of ranolazine would represent a fourth product-related revenue stream for CV Therapeutics."

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy).

"Considering the well-established ne
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. Nabriva Therapeutics Announces Appointment of New CEO
4. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
5. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
6. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
7. Tobira Therapeutics Inc. Announces Senior Management Team
8. Duska Therapeutics Obtains Standard & Poors Listing
9. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
10. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
11. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Whitehouse Laboratories ... joined the Morris County (New Jersey) Chamber of ... a leading business organization in the North Jersey ... further engage some key clients in the pharmaceutical ... the geographic area. Membership enables Whitehouse Laboratories a ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Global ... by 2019 growing at an estimated CAGR of ... for healthy food products with least ecological impacts, ... mineral fertilizers to boost crop yield more effectively ... products that can improve the return on investments. ...
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... "Sheikh Hamdan Bin Rashid Al Maktoum Awards for Medical ... Dubai, United Arab Emirates , on ... ) , The Carter Center which ... Services is actively involved in numerous programs that aim ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... , , , , , , , , ... leading provider of biopharmaceutical products in China, announced today,that it has ... commence a human clinical trial for its vaccine,against human enterovirus 71 ... the first clinical trial application for HFMD vaccine,submitted in China. , ...
... SBS , CALGARY, Dec. 24 /PRNewswire-FirstCall/ - SemBioSys Genetics ... on plant-produced Apo AI(Milano) in light of the Apo ... Company, of Parsippany, New Jersey. , "The Medicines Company,s ... program is a strong endorsement of Apo AI(Milano) and ...
... to dye the Chicago River green on St. Patrick,s Day. ... scenes. And now researchers at Northwestern University have used it ... useful tool is the dye fluorescein, and Jiaxing Huang, assistant ... of Engineering and Applied Science, and his research group have ...
Cached Biology Technology:Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 2Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 3Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 4SemBioSys updates progress on Apo AI(Milano) 2SemBioSys updates progress on Apo AI(Milano) 3An easy way to see the world's thinnest material 2
(Date:11/7/2014)...  In conjunction with the Glendale ... Foundation of the Verdugos has announced the " GLENDALE ... $250,000 initiative to keep the Verdugo Regional Crime Lab operational ... months of existence, the Lab has processed more than 400 ... enforcement. "Because our number one priority is the ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
(Date:11/4/2014)... nature, the right amount of death at the right ... according to new research that could help in understanding ... stocks. , In a paper in the journal ... researcher and European colleagues conclude that the kind of ... loss of individuals, or mortality, depends on the size ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... SAN FRANCISCO: The Society for Integrative and Comparative Biology ... biological organizations, will hold its annual meeting at the ... from January 3 to 7, 2013. More than 1,500 ... evolution, physiology, neurobiology, and biomechanics, offering journalists a rich ...
... Missouri researcher M. Frederick Hawthorne as recipient of the ... the country to scientists. Hawthorne is the director of ... the University of Missouri, as well as Curators, Distinguished ... proud to honor these inspiring American innovators," President Obama ...
... MASS. -- What happens when graduate students in biology are ... into the unknowns of genuine research, not worry about getting ... Physiology course, one outcome has beenparadoxicallyan extraordinary level of new ... Dec. 21 issue of Science magazine, several scientists ...
Cached Biology News:Integrative and comparative biologists to discuss latest research 2Integrative and comparative biologists to discuss latest research 3President Obama honors MU researcher with National Medal of Science 2Having serious fun in the MBL physiology course 2
... For separation and ... Efficient separation of nuclei from ... in sample complexity, greatly facilitating ... Subfractionation of nucleic acid binding ...
... Many modifications of Eagle's ... the original formulation. The most ... Modified Eagle's,Medium. DME is a ... Eagle [MEM] that contains a ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
Biology Products: